Astellas inks neurodegenerative collaboration deal

Share this article:

Astellas continues to expand its list of 2013 partnerships. The drug maker and co-developer Mitokyne announced Monday an R&D agreement to pursue novel drugs that improve mitochondrial functions, with the overall goal being to create drug candidates that could treat genetic, metabolic or neurodegenerative disorders, and even conditions associated with aging. Mitokyne will handle R&D, while Astellas will pick up the clinical development and commercialization side of things.

Monday's announcement is one of a series of recent collaborations, which includes the June R&D agreement with Cytokinetics to target muscle-weakening diseases, May's announcement that it was teaming up with Amgen for cardiovascular and bone diseases, and April's announcement that Astellas and GSK were working on an anemia treatment that dupes the body into thinking it is at a higher altitude to stimulate red blood cell development.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.